Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 8/20 | 0.48 |
| ▸ | FYN | P06241 | 7/20 | 0.48 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.45 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14767490 | 0.92 | TTK (0.47) | TTKFYNZAP70KARS1PDE10A | |
| SCHEMBL12409298 | 0.90 | MAPK1 (0.48) | TTKFYNPDE10AGAAADORA3 | |
| SCHEMBL12409242 | 0.90 | TTK (0.56) | TTKFYNADORA3 | |
| SCHEMBL2178112 | 0.89 | TTK (0.56) | TTKFYNZAP70KARS1MEN1 | |
| SCHEMBL2179881 | 0.89 | CFTR (0.54) | TTKFYNZAP70KARS1MEN1 | |
| SCHEMBL12409252 | 0.87 | ZAP70 (0.48) | TTKFYNZAP70KARS1PDE10A | |
| SCHEMBL12409240 | 0.86 | FYN (0.53) | TTKFYNZAP70KARS1PDE10A | |
| SCHEMBL12409234 | 0.85 | FYN (0.54) | TTKFYNMEN1GAAKMT2A | |
| SCHEMBL12409235 | 0.85 | PAX8 (0.48) | TTKFYNZAP70KARS1PDE10A | |
| SCHEMBL3469243 | 0.82 | ADORA3 (0.51) | TTKFYNZAP70KARS1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2567960-A2 | Imidazo[1,2-a]pyrazine compounds for treatment of viral infections such as hepatitis | Biofocus DPI Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| EP-2193131-B1 | IMIDAZO[1,2-A]PYRAZINE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS SUCH AS HEPATITIS | BIOFOCUS DPI LTD (GB) | 2013-01-30 | — | — | EP | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| EP-2193131-A2 | IMIDAZO[1,2-A]PYRAZINE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS SUCH AS HEPATITIS | Biofocus DPI Limited (GB) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009024585-A2 | IMIDAZO [1,2-A] PYRAZINE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS SUCH AS HEPATITIS | BIOFOCUS DPI LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024585-A2 | IMIDAZO [1,2-A] PYRAZINE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS SUCH AS HEPATITIS | BIOFOCUS DPI LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | CYP3A5, HAVCR2, CYP3A43 | TTK 3239/4885FYN 3511/4885ZAP70 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.